Lung Bioavailability With Continuous or Discontinuous Nebulization

EFFECT OF DRUG TARGETING NEBULIZATION ON LUNG DELIVERY

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01913184

Enrollment

Registered

2013-07-31

Start date

2012-04-30

Completion date

2012-06-30

Last updated

2013-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

To compare the continuous and sicontinuous delivery of drug with AKITA.

Interventions

DEVICEAKITA

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* no lung disease * no allergy

Exclusion criteria

* smoker

Design outcomes

Primary

Measure	Time frame
Lung bioavailability by urinary monitoring	24h after the nebulization

Secondary

Measure	Time frame
Duration of the nebulization	After the nebulization

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026